Rise in prevalence of lysosomal diseases, the introduction of orphan medicines, and expanding government programs and investments for the development of innovative medications drive the growth of the global lysosomal disease treatment market.
PORTLAND, Ore., Sept. 6, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Lysosomal Disease Treatment Market by Disease Type (Gaucher's Diseases, Fabry Diseases, Pompe's Syndrome, Mucopolysaccharidosis, Others), by Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others), by End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031". According to the report, the global lysosomal disease treatment industry generated $7.6 billion in 2021, and is anticipated to generate $14.1 billion by 2031, witnessing a CAGR of 6.4% from 2022 to 2031.
Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/5655
Prime determinants of growth
Rise in prevalence of lysosomal diseases, the introduction of orphan medicines, and expanding government programs and investments for the development of innovative medications drive the growth of the global lysosomal disease treatment market. However, lack of effective treatments for lysosomal diseases and their high cost restrict the market growth. Moreover, increase in awareness regarding preventative measures for lysosomal diseases and lysosomal disease treatment market trends are anticipated to present new opportunities in the coming years.
Covid-19 Scenario
- The outbreak of the Covid-19 pandemic had a negative impact on the global lysosomal disease treatment market, as the focus of medical professionals, governments, and general public moved to containing the spread of the virus. This factor resulted in a significant decline in demand for the lysosomal disease treatments across several sectors, particularly the health and pharmaceutical sector.
- The main cause of the interruptions experienced by patients getting treatments for lysosomal disorder in hospitals was the risk of infection spread. In order to maintain the social distancing norms, the number of clients decreased considerably. People stopped going to clinics and hospitals unless they had an emergency.
Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/5655?reqfor=covid
The Gaucher's Diseasessegment to maintain its leadership status throughout the forecast period
Based on disease type, the Gaucher's diseases segment held the highest market share in 2021, accounting for nearly two-fifths of the global lysosomal disease treatment market, and is estimated to maintain its leadership status throughout the forecast period, owing to increase in prevalence of Gaucher's disease and patients seeking treatments for Gaucher's disease. However, the Fabry diseases segment is projected to manifest the highest CAGR of 7.3% from 2022 to 2031. This is owing to the rise in incidence of Fabry diseases, and approval of Fabrazyme which shows significant results in the treatment of Fabry diseases.
The Enzyme replacement therapy segment to maintain its leadership status throughout the forecast period
Based on type of therapy, the enzyme replacement therapy segment held the highest market share in 2021, accounting for around three-fourths of the global lysosomal disease treatment market, and is estimated to maintain its leadership status throughout the forecast period. Moreover, the same segment is projected to manifest the highest CAGR of 6.6% from 2022 to 2031. This is owing to the high effectiveness of enzyme replacement therapy in lysosomal disease treatments, strong product pipeline of novel enzyme replacement therapies and increase in patients seeking the treatment. The report also analyzes segments such as stem cell therapy, substrate reduction therapy, and others.
Purchase Inquire:https://www.alliedmarketresearch.com/purchase-enquiry/5655
The hospitals segment to maintain its lead position during the forecast period
Based on distribution channel, the hospitals segment accounted for the largest share in 2021, contributing to more than half of the global lysosomal disease treatment market, and is projected to maintain its lead position during the forecast period. Moreover, the same segment is expected to portray the largest CAGR of 7.1% from 2022 to 2031, owing to the large number of patient visits to hospitals for the diagnosis and treatment of lysosomal disease. The report also analyzes clinics segment.
North America to maintain its dominance by 2031
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than two-fifths of the global lysosomal disease treatment market and is expected to maintain its dominance throughout the forecast period. This is owing to the high prevalence of lysosomal diseases, the well-established healthcare facilities, recent technological advancements, and rise in demand for early diagnosis of lysosomal diseases in the region. Moreover, the Asia-Pacific region is expected to witness the fastest CAGR of 7.7% from 2022 to 2031. This is owing to an increase in population suffering from lysosomal diseases and the rise in awareness about lysosomal diseases and its treatments in the region.
Leading Market Players:
- Amicus Therapeutics, Inc.
- Alexion Pharmaceuticals, Inc.
- BioMarin
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Sigilon Therapeutics, Inc.
These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Avenue Basic Plan | Library Access | 1 Year Subscription |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter
"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."
Trending Reports in Healthcare Industry (Book Now with 10% Discount + Covid-19 scenario):
Oncology-Cancer Drugs Market By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2021-2030
HIV Drugs Market By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2021-2030
Disposable Gloves Market by Type (Natural Rubber Gloves, Nitrile Gloves, Vinyl Gloves, Neoprene, Polyethylene, and Others), Application (Medical and Non-Medical) and Form (Powdered and Non-Powdered): Global Opportunity Analysis and Industry Forecast, 2019-2030
Digital Therapeutics Market by Product (Software and Devices), Sales Channel (Business-to-Business and Business-to-Consumers), Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS), Disease Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID) and Others: Global Opportunity Analysis and Industry Forecast, 2022-2031
Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2030
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
